Table 1.
Baseline characteristics of the study population according to quartiles of METS-IR.
| Characteristics | METS-IR quartiles | P-value | |||
|---|---|---|---|---|---|
| Q1 (<37.32) | Q2 (37.32-42.47) | Q3 (42.48-48.22) | Q4 (>48.22) | ||
| Participants, n | 3507 | 3507 | 3508 | 3510 | |
| Age, year | 52.36 ± 12.20 | 51.57 ± 12.07 | 52.31 ± 11.74 | 51.90 ± 11.93 | 0.018 |
| Men, n (%) | 1904 (54.29%) | 1879 (53.58%) | 1931 (55.05%) | 1915 (54.56%) | <0.001 |
| Body mass index, kg/m2 | 22.61 ± 1.61 | 24.74 ± 1.45 | 26.61 ± 1.86 | 29.59 ± 2.89 | <0.001 |
| Heart rate, bpm | 80.41 ± 10.85 | 80.67 ± 10.20 | 81.22 ± 10.18 | 82.82 ± 10.78 | <0.001 |
| SBP, mmHg | 143.97 ± 20.51 | 145.43 ± 20.57 | 145.92 ± 20.46 | 148.07 ± 20.96 | <0.001 |
| DBP, mmHg | 87.53 ± 14.35 | 89.22 ± 14.28 | 90.34 ± 14.17 | 92.61 ± 14.67 | <0.001 |
| Current smoking, n (%) | 615 (17.54%) | 1082 (30.85%) | 1300 (37.06%) | 1526 (43.48%) | <0.001 |
| Current drinking, n (%) | 572 (16.31%) | 1013 (28.89%) | 1234 (35.18%) | 1390 (39.60%) | <0.001 |
| Laboratory parameters | |||||
| UA, mmol/L | 293.85 ± 81.26 | 330.34 ± 84.67 | 355.05 ± 91.51 | 377.28 ± 99.33 | <0.001 |
| eGFR, mL/min/1.73 m2 | 97.14 ± 18.64 | 96.47 ± 17.55 | 96.68 ± 17.51 | 97.35 ± 18.55 | 0.153 |
| Cys C, mg/L | 0.90 ± 0.34 | 0.92 ± 0.33 | 0.93 ± 0.34 | 0.95 ± 0.31 | <0.001 |
| TC, mmol/L | 4.45 ± 0.95 | 4.42 ± 0.94 | 4.48 ± 1.00 | 4.53 ± 1.04 | <0.001 |
| TG, mmol/L | 1.19 ± 0.52 | 1.60 ± 0.83 | 1.96 ± 1.04 | 2.74 ± 2.02 | <0.001 |
| HDL-C, mmol/L | 1.31 ± 0.30 | 1.09 ± 0.22 | 0.99 ± 0.20 | 0.88 ± 0.18 | <0.001 |
| LDL-C, mmol/L | 2.65 ± 0.82 | 2.78 ± 0.81 | 2.75 ± 0.85 | 2.71 ± 0.83 | <0.001 |
| HbA1c, % | 6.01 ± 1.22 | 6.17 ± 1.25 | 6.18 ± 1.24 | 6.22 ± 1.26 | <0.001 |
| FPG, mmol/L | 4.68 ± 0.94 | 5.03 ± 1.51 | 5.36 ± 2.02 | 5.84 ± 2.36 | <0.001 |
| Hcy, mmol/L | 14.40 ± 6.92 | 14.58 ± 6.79 | 14.96 ± 7.04 | 15.08 ± 7.33 | <0.001 |
| hsCRP, mg/L | 3.14 (1.23-7.45) | 3.02 (1.15-7.17) | 3.15 (1.15-7.65) | 3.27 (1.17-7.80) | 0.319 |
| Medical histories, n (%) | |||||
| Hyperlipidemia | 1982 (56.52%) | 2010 (57.31%) | 2072 (59.06%) | 2140 (60.97%) | <0.001 |
| Coronary heart disease | 489 (13.94%) | 435 (12.40%) | 541 (15.42%) | 708 (20.17%) | <0.001 |
| Diabetes | 965 (27.52%) | 923 (26.32%) | 1001 (28.53%) | 1127 (32.11%) | <0.001 |
| Charlson comorbidity index | 0.005 | ||||
| 0 | 1622 (46.25%) | 1637 (46.68%) | 1602 (45.67%) | 1532 (43.65%) | |
| 1 | 944 (26.92%) | 1029 (29.34%) | 1037 (29.56%) | 1051 (29.94%) | |
| 2 or more | 941 (26.83%) | 841 (23.98%) | 869 (24.77%) | 927 (26.41%) | |
| Follow-up duration, years | 4.80 (1.80-7.50) | 4.70 (1.70-7.60) | 4.80 (1.80-7.50) | 5.00 (1.80-7.60) | 0.332 |
Data are mean (standard deviation), n (%), or median (interquartile range).
METS-IR, metabolic score for insulin resistance; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular fltration rate; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HbA1c, hemoglobin A1c; FPG, fasting plasma glucose; Hcy, homocysteine; UA, uric acid; hsCRP, high-sensitivity C-reactive protein; Cys C, cystatin C.